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ABSTRACT
Introduction The clinical significance of subsegmental 
pulmonary embolism (SSPE) is currently unclear. Although 
growing evidence from observational studies suggests that 
withholding anticoagulant treatment may be a safe option 
in selected patients with isolated SSPE, most patients 
with this condition receive anticoagulant treatment, which 
is associated with a 90- day risk of recurrent venous 
thromboembolism (VTE) of 0.8% and major bleeding of 
up to 5%. Given the ongoing controversy concerning the 
risk- benefit ratio of anticoagulation for isolated SSPE and 
the lack of evidence from randomised- controlled studies, 
the aim of this clinical trial is to evaluate the efficacy and 
safety of clinical surveillance without anticoagulation in 
low- risk patients with isolated SSPE.
Methods and analysis SAFE- SSPE (Surveillance vs. 
Anticoagulation For low- risk patiEnts with isolated 
SubSegmental Pulmonary Embolism, a multicentre 
randomised placebo- controlled non- inferiority trial) 
is an international, multicentre, placebo- controlled, 
double- blind, parallel- group non- inferiority trial 
conducted in Switzerland, the Netherlands and Canada. 
Low- risk patients with isolated SSPE are randomised 
to receive clinical surveillance with either placebo 
(no anticoagulation) or anticoagulant treatment with 
rivaroxaban. All patients undergo bilateral whole- leg 
compression ultrasonography to exclude concomitant deep 
vein thrombosis before enrolment. Patients are followed for 
90 days. The primary outcome is symptomatic recurrent 
VTE (efficacy). The secondary outcomes include clinically 
significant bleeding and all- cause mortality (safety). 
The ancillary outcomes are health- related quality of life, 
functional status and medical resource utilisation.
Ethics and dissemination The local ethics committees 
in Switzerland have approved this protocol. Submission 
to the Ethical Committees in the Netherlands and Canada 
is underway. The results of this trial will be published in a 
peer- reviewed journal.
Trial registration number NCT04263038.
INTRODUCTION
Depending on thromboembolic burden 
and patient factors, the clinical spectrum 
of pulmonary embolism (PE) ranges from 
asymptomatic cases to massive PE with 
haemodynamic collapse.1 2 Anticoagulant 
treatment for at least 3 months effectively 
reduces the risk of recurrent venous throm-
boembolism (VTE).3 4 The benefit of anti-
coagulation, however, comes at the cost of 
potentially disabling and life- threatening 
bleeding events, with a 90- day risk of major 
bleeding of up to 5%.5–8
The widespread introduction and techno-
logical advances of multi- detector CT pulmo-
nary angiography (CTPA) have led to an 80% 
increase in the diagnosis of acute PE between 
1998 and 2006.9 This increase is in part due 
to an increase in the detection of small, 
peripheral PE limited to the subsegmental 
pulmonary arteries, that is, subsegmental PE 
Strengths and limitations of this study
 ► This is the first randomised trial comparing the safe-
ty and efficacy of a management strategy without 
anticoagulation and anticoagulant treatment in low- 
risk patients with isolated subsegmental pulmonary 
embolism (SSPE).
 ► We chose patient- centred outcomes and economi-
cally relevant efficiency measures that are relevant 
to both patient and healthcare professionals.
 ► As patients with isolated SSPE and a high risk of ad-
verse events (eg, patients with cancer) are excluded 
from this trial due to safety reasons, generalisability 
of the results will be limited to low- risk patients with 
isolated SSPE.
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(SSPE),10 11 which currently comprise 10%–15% of cases 
with PE.12–15 However, the clinical significance of isolated 
SSPE is questionable. Epidemiological evidence suggests 
overdiagnosis: despite the increase in PE diagnoses in 
recent years, PE- related mortality has remained stable 
or has even decreased.9 16 The positive predictive value 
of CTPA to diagnose SSPE is as low as 25% (compared 
with a composite reference standard with ventilation- 
perfusion lung scanning with or without lower limb 
venous ultrasonography, or pulmonary digital- subtraction 
angiography),17 and interobserver agreement between 
radiologists for SSPE diagnosis is only fair,18 indicating 
that differentiation between true emboli and artefacts in 
the subsegmental pulmonary arteries is difficult. Small 
PE may even occur in healthy individuals without clinical 
consequences,19–21 suggesting that SSPE may be the result 
of the physiological filter function of the lung to protect 
the systemic circulation.
Whether patients with isolated SSPE benefit from anti-
coagulant treatment is currently uncertain.4 There is 
growing evidence from observational studies that with-
holding anticoagulation may be safe in patients with 
isolated SSPE who are at low risk of recurrent or progres-
sive VTE,22–27 but most of such patients currently receive 
anticoagulant treatment,28–31 potentially exposing them 
to an unnecessary risk of bleeding. Given the ongoing 
controversy and clinical equipoise about the risk- benefit 
ratio of anticoagulation for isolated SSPE, we aim to eval-
uate the efficacy and safety of clinical surveillance without 
anticoagulation compared with standard anticoagulation 
treatment in low- risk patients with SSPE in a randomised 
clinical trial.
METHODS AND ANALYSIS
This study protocol has been developed according to the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials guidelines.32
Objectives and hypotheses
The primary objective of this randomised trial is to 
compare the frequency of symptomatic, recurrent VTE in 
low- risk patients with isolated SSPE randomised to receive 
clinical surveillance plus placebo or clinical surveillance 
plus anticoagulant treatment with rivaroxaban. As a 
secondary objective, the frequency of clinically significant 
bleeding and all- cause mortality is compared in the two 
groups. Ancillary endpoints include health- related quality 
of life, functional status, and medical resource utilisation. 
We hypothesise that clinical surveillance without antico-
agulant treatment is non- inferior to anticoagulation in 
terms of recurrent VTE, while resulting in fewer clinically 
significant bleeding events and similar all- cause mortality. 
We also hypothesise that clinical surveillance, compared 
with anticoagulation, improves health- related quality of 
life and functional status and reduces medical resource 
utilisation.
Study design and setting
SAFE- SSPE (clinical Surveillance vs. Anticoagulation 
For low- risk patiEnts with isolated SubSegmental Pulmo-
nary Embolism) is an investigator- initiated, multicentre, 
randomised, placebo- controlled, double- blind, parallel- 
group non- inferiority trial. Patients with isolated SSPE at 
low risk for VTE progression or recurrence and without 
concomitant deep vein thrombosis (DVT) are randomly 
assigned in a 1:1 ratio to receive clinical surveillance plus 
placebo or clinical surveillance plus anticoagulation with 
rivaroxaban (figure 1). Randomisation is blocked and 
stratified by study site. To ensure concealment of allo-
cation, the allocation sequence is generated by a data 
manager not involved in the study, using a computer- 
generated randomisation schedule. All participants, care 
providers, investigators, study personnel, members of the 
outcomes adjudication committee, data management 
personnel and analysts are blinded to group assignment. 
Eligible patients are recruited in at least 27 university and 
medium- volume to high- volume non- university teaching 
hospitals in Switzerland, the Netherlands and Canada.
Selection of patients
Consecutive patients aged ≥18 years with objectively 
diagnosed symptomatic or asymptomatic isolated SSPE 
on CTPA based on the assessment of the local radiolo-
gist at the time of patient presentation are eligible for 
study participation after provision of informed consent 
(table 1). Isolated SSPE is defined as multi- detector CTPA 
demonstrating an intraluminal filling defect in ≥1 subseg-
mental pulmonary artery (4th order or higher) without 
filling defects visualised at more proximal pulmonary 
artery levels.24 33 34 Isolated subsegmental defects are clas-
sified as either single (one subsegmental vessel involved) 
or multiple (≥2 subsegmental vessels involved). Patients 
with both symptomatic and incidentally detected, asymp-
tomatic isolated SSPE are potentially eligible because 
symptoms of PE may be subtle and difficult to elucidate, 
and symptomatic and asymptomatic PE appear to have 
a similar prognosis.35 We will enrol both patients with 
single and multiple isolated SSPE because there is no 
convincing evidence that these conditions are prognos-
tically different.
The exclusion criteria were selected based on a high 
early risk of VTE recurrence (≥8%), the presence of 
cardiopulmonary compromise (ie, hypotension or 
hypoxaemia), contraindications to anticoagulant treat-
ment with rivaroxaban, and a high risk of confounding 
(table 2).4 14 36–44 All exclusion criteria are listed in table 2. 
Because PE usually originates from a thrombus in the 
deep leg veins,45 potentially eligible patients systemat-
ically receive a single bilateral whole- leg compression 
ultrasonography (CUS) examination to exclude concom-
itant DVT, which is a well- known prognostic factor for 
mortality in patients with PE and represents an absolute 
indication for therapeutic anticoagulation.46 If a proximal 
or distal DVT (with an incompressible distal vein diam-
eter of ≥5 mm)47 is detected, patients are excluded from 
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study participation and treated at the discretion of their 
managing physician. We cannot fully exclude the small 
possibility that an eligible patient with SSPE in whom the 
presence of a leg vein DVT was ruled out by a bilateral 
whole- leg CUS may have a concomitant isolated iliac vein 
thrombosis or a thrombosis at an unusual site (eg, in the 
cerebral, splanchnic or ovarian veins). However, these are 
rare thrombotic conditions that often occur in specific 
clinical situations representing study exclusion criteria 
(cancer, pregnancy, puerperium).48 The risk that such 
patients would present with an isolated SSPE is even lower. 
Although whole- leg CUS is not an effective method to 
exclude an isolated iliac vein thrombosis, a meta- analysis 
of randomised trials and prospective management studies 
Figure 1 Overview of the study design. SAFE- SSPE is a randomised, placebo- controlled, parallel- group non- inferiority 
trial. Low- risk patients with isolated SSPE without concomitant DVT are randomly assigned in a 1:1 ratio to receive placebo 
(‘clinical surveillance group’) or anticoagulant treatment with rivaroxaban (‘anticoagulation group’). The primary study outcomes 
are symptomatic recurrent VTE within 90 days of randomisation. Secondary outcomes include clinically significant bleeding 
and all- cause mortality, and ancillary outcomes will be health- related quality of life, functional status and medical resource 
utilisation. DVT, deep vein thrombosis; PE, pulmonary embolism; SSPE, subsegmental pulmonary embolism; VTE, venous 
thromboembolism.
Table 1 Study population, intervention, control and outcomes
Population
Consecutive adult low- risk patientswith an objective diagnosis of isolated subsegmental PE who have no 
concomitant DVT.
Intervention Clinical surveillance plus a matching rivaroxaban placebo, one tablet two times per day for the first 21 days, 
followed by one tablet once daily for the remaining 90- day study period. Clinical surveillance is done at 10, 
30 and 90 days following randomisation by phone or by in- person visits, depending on local practice. At each 
contact, trained study personnel complete an assessment of symptoms and review for suspected recurrent 
VTE and bleeding using a checklist of predefined questions. Patients are also instructed to contact study 
personnel or report to the ED immediately if any symptoms/signs compatible with recurrent VTE or significant 
bleeding occur.
Control Clinical surveillance plus anticoagulation with rivaroxaban, dosed at 15 mg two times per day for the first 21 
days, followed by 20 mg once daily for the remaining 90- day study period. The same surveillance schedule as 
in the clinical surveillance group is used. Patients also receive the same instructions to contact study personnel 
or report to the ED if any signs or symptoms of VTE or significant bleeding occur.
Outcomes Primary outcome: recurrent, clinically symptomatic, objectively confirmed VTE within 90 days of randomisation, 
defined as recurrent fatal or non- fatal PE or lower limb DVT (efficacy).
Secondary outcomes: clinically significant bleeding and all- cause mortality at 90 days of randomisation (safety).
Ancillary outcomes: health- related quality of life, functional status and medical resource utilisation at 90 days of 
randomisation.
In a post- hoc analysis, radiological interobserver agreement for SSPE will be assessed.
DVT, deep vein thrombosis; ED, emergency department; PE, pulmonary embolism; SSPE, subsegmental pulmonary 
embolism; VTE, venous thromboembolism.
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has convincingly shown that in patients with suspected 
DVT in whom DVT has been excluded by a single 
whole- leg CUS and in whom anticoagulation is withheld, 
the risk of recurrent VTE is very low.49
Intervention
Patients in the intervention group receive clinical surveil-
lance and a matching rivaroxaban placebo orally using 
the same dosing schedule, frequency of administration 
and duration of treatment as for rivaroxaban (see later). 
Clinical surveillance is done during the follow- up inter-
views by phone or in- person, depending on local practice. 
At each contact, trained study personnel complete an 
assessment of symptoms and review for suspected recur-
rent VTE and bleeding. If patients report symptoms or 
signs suggestive of recurrent VTE or significant bleeding, 
they are asked to present immediately to an emergency 
department (ED) for evaluation.
Control
Patients who are assigned to the anticoagulation group 
receive oral rivaroxaban 15 mg two times per day for 
the first 21 days, followed by 20 mg once daily for the 
remaining 90- day study period. After completion of the 
treatment period, the study drug is discontinued. The 
same surveillance schedule as in the intervention group 
is used.
Study procedures
Patients are screened for eligibility if they receive a CTPA 
in the ED or within 72 hours of hospitalisation to rule- in 
or rule- out PE, or if they present to an outpatient service 
within 72 hours of SSPE diagnosis. Eligibility criteria are 
assessed for all consecutive patients with suspected SSPE, 
and potentially eligible patients are asked to provide 
informed consent by investigators or their delegates 
(online supplemental file 1 for an English language 
Table 2 Exclusion criteria and their rationale
Exclusion criterion Rationale
Presence of leg DVT or upper extremity DVT (subclavian vein or above) Absolute indication for therapeutic 
anticoagulation
Active cancer High risk of recurrent VTE if left untreated36
History of ≥1 prior episode of unprovoked VTE (±thrombophilia)37 High risk of recurrent VTE after stopping 
anticoagulation38–40
Clinical instability (systolic blood pressure <100 mm Hg or arterial oxygen 
saturation <92% at ambient air) at the time of presentation
Risk of clinical deterioration4 14 41
Active bleeding or at high risk of bleeding (eg, signs of active bleeding, 
ischaemic stroke during preceding <10 days,42 major gastrointestinal 
bleeding during preceding <3 months, intracranial or intraocular bleeding <6 
months,42 major trauma or surgery during preceding <1 month,42 43 platelets 
<75 ×10ˆ9/L 3 44 or double anti- platelet therapy at the time of enrolment)
Contraindication to rivaroxaban
Severe renal failure (creatinine clearance <30 mL/min) Contraindication to rivaroxaban
Severe liver insufficiency (Child- Pugh B and C) Contraindication to rivaroxaban
Concomitant use of strong CYP3A4 inhibitors (ie, HIV protease inhibitors 
(saquinavir, indinavir, ritonavir, nelfinavir, amprenavir, lopinavir, atazanavir, 
fosamprenavir, tipranavir, darunavir), systemic azole antifungals (ie, 
ketoconazole, itraconazole, voriconazole or posaconazole)) or strong 
CYP3A4 inducers (ie, rifampicin, rifabutin, rifapentin, phenytoin, 
phenobarbital, primidone, carbamazepine or St. John’s Wort)
Contraindication to rivaroxaban
Known hypersensitivity to rivaroxaban Contraindication to rivaroxaban
Need for therapeutic anticoagulation for another reason (atrial fibrillation/
flutter, mechanical heart valves, previous VTE, known antiphospholipid 
antibody syndrome with unprovoked VTE)
Randomisation to placebo unethical
Therapeutic anticoagulation for >72 hours for any reason at the time of 
screening
Could confound study outcomes
Hospitalised for >72 hours prior to the diagnosis of isolated SSPE (hospital- 
acquired VTE)
Could confound study outcomes due to 
influence of cotreatments
Known pregnancy or breast feeding Contraindication to rivaroxaban
Lack of safe contraception in women of childbearing potential Rivaroxaban is contraindicated in pregnancy
Refusal or inability to provide informed consent Unethical
Prior enrolment in this trial Confounds study outcomes
DVT, deep vein thrombosis; VTE, venous thromboembolism
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example of the informed consent form). For those 
who consent to participate, a bilateral whole- leg CUS 
is performed by qualified examiners (eg, radiologists, 
vascular specialists or emergency physicians). All eligible 
and consenting patients without DVT are randomised 
to receive clinical surveillance or anticoagulation with 
rivaroxaban, and trained study personnel collect baseline 
data by reviewing medical records, medication lists, labo-
ratory results that have been obtained as part of routine 
care, radiology reports and by patient interview (table 3). 
After provision of the assigned study medication, the 
participants are asked to immediately start with the treat-
ment. In addition, all participants receive a patient diary 
consisting of two parts: the first contains important infor-
mation about the study, and the second part consists of 
a diary to record dates and type of outcomes in order to 
minimise recall bias (table 3).
Participants are followed for 90 days using phone or 
in- person interviews at 10, 30 and 90 days after randomisa-
tion (online supplemental file 1). Trained study personnel 
contacts patients, family members, and/or primary care 
physicians and review medical charts to obtain informa-
tion about outcome events. At the end of the treatment 
period, patients are instructed to return the medication 
bottles and the patient diary. Drug- adherence is assessed 
by counting the pills in the returned medication bottles 
(table 3).
Data collection and quality
Data are collected using an electronic database (secu-
Trial). The following measures are implemented to 
ensure optimal data quality and completeness: (1) 
training of study personnel in the methods of data 
abstraction, patient inquiry and data recording, (2) 
recording of study data on standardised electronic case 
report forms, (3) operations manual providing informa-
tion on definitions and acceptable data sources for all 
variables, (4) central data monitoring with generation of 
statistical reports and individual data checks and (5) risk 
based on- site monitoring (ie, based on key performance 
indicators such as inappropriate recruitment rate, change 
of principal investigator, high number of queries raised 
by central data monitoring, high number of protocol 
deviations, etc).
Criteria for discontinuation of the study medication and 
unblinding
In participants requiring prophylactic or therapeutic anti-
coagulation during the study period for reasons other 
than the index SSPE or if treatment with another prohib-
ited agent is necessary (ie, strong CYP3A4 inhibitors or 
inducers, dual antiplatelet therapy, GP IIb/IIIa inhibi-
tors), the study drug should be temporarily interrupted 
and restarted as soon as possible following discontinua-
tion of the prohibited medication. Patients who develop 
any condition requiring permanent therapeutic anticoag-
ulation (eg, atrial fibrillation) should permanently discon-
tinue the study drug. If an invasive procedure or surgical 
intervention is required, the study medication should be 
stopped at least 24 hours prior to an elective intervention, 
or immediately for emergency procedures. If objectively 
confirmed recurrent VTE or pregnancy is diagnosed 
during the treatment period, the study drug should be 
discontinued and treatment allocation unblinded. Simi-
larly, in case of major bleeding, the study drug should be 
stopped and unblinding may be necessary if emergency 
anticoagulation reversal is indicated.
Primary and secondary outcomes
The primary (efficacy) outcome is the proportion of 
recurrent, clinically symptomatic, objectively confirmed 
VTE within 90 days of randomisation, defined as recur-
rent PE or lower limb DVT.50 51 The objective diagnostic 
criterion for PE, based on available radiographic reports, 
is a new intraluminal filling defect on CTPA or pulmo-
nary angiography; a perfusion defect involving at least 
75% of a segment, with corresponding normal ventilation 
(ie, high probability lung scan); the confirmation of new 
PE at autopsy; or objectively confirmed proximal DVT 
of the lower extremity in patients with symptoms of PE. 
The objective diagnosis of DVT is the non- compressibility 
of a venous segment on CUS or an intraluminal filling 
defect on contrast venography. Because compression of 
iliac veins and the inferior vena cava may be technically 
difficult, additional diagnostic criteria for iliac and caval 
DVT also include abnormal duplex flow patterns compat-
ible with thrombosis or an intraluminal filling defect on 
CT or MRI venography.52 Both proximal and distal DVTs 
are considered.
Separate secondary (safety) outcomes include the 
proportion of clinically significant bleeding and all- cause 
mortality 90 days following randomisation. Clinically 
significant bleeding is a composite endpoint of major and 
clinically relevant non- major bleeding. Major bleeding is 
defined as fatal bleeding, symptomatic bleeding at crit-
ical sites (intracranial, intraspinal, intraocular, retroper-
itoneal, intra- articular, pericardial or intramuscular with 
compartment syndrome), or bleeding with a reduction 
of haemoglobin ≥20 g/L, or bleeding leading to trans-
fusion of ≥2 units of packed red blood cells according 
to the definition of the International Society on Throm-
bosis and Haemostasis.53 Clinically relevant non- major 
bleeding is defined as overt bleeding that does not meet 
criteria for major bleeding but is associated with a medical 
intervention, unscheduled physician contact (visit or tele-
phone call), temporary cessation of the study drug, pain 
or impairment of activities of daily life.54
Information about the date, type and circumstances of 
outcome events is obtained from patients, family members, 
and/or healthcare providers during the follow- up inter-
views or by reviewing medical charts. In patients who 
experience recurrent VTE, the radiographic report and 
images confirming VTE recurrence are obtained. For 
patients who died during follow- up, the cause of death 
based on medical reports, death certificates and autopsy 
reports (if available) is recorded. All medical outcome 
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events are reviewed and adjudicated by a committee of 
three independent clinical experts unaware of treatment 
assignment. Based on available information, death is adju-
dicated as PE- related, due to major bleeding (any death 
following an intracranial haemorrhage or a bleeding 
episode leading to haemodynamic deterioration), due to 
another cause or due to an undetermined cause. Death 
is considered PE- related in the following situations: (1) 
Table 3 Study schedule
Study period
Enrolment 
and 
allocation Baseline Post- allocation Close- out
Visit/follow- up phone call 1 2✆††‡‡ 3✆†† 4✆††
Time (day with allowed visit window) d0 d0 d10 (7–12) d30 (28–35) d90 (88–95)
Eligibility screen (inclusion/exclusion criteria) x         
Patient information and informed consent x         
Bilateral whole- leg compression ultrasonography* x         
Randomisation x         
Demographic characteristics x       
Risk factors for venous thromboembolism   x       
Symptoms of venous thromboembolism   x       
Comorbid conditions   x       
Physical examination findings   x       
Laboratory test results   x       
Imaging findings   x       
Concomitant treatments   x       
Health- related quality of life (PEmb- QoL)†   x   x x
Functional status‡         x
Treatment setting   x       
Distribution and instruction of study drug   x       
Daily intake of study medication: placebo or rivaroxaban     x (immediate start on day 0)
Instructions and distribution of patient diary§   x       
Recurrent venous thromboembolism     x x x
Clinically significant bleeding     x x x
All- cause mortality     x x x
Medical resource utilisation     x x x
Time to symptom resolution     x x x
New concomitant treatments     x x x
Interruption of the study drug     x x x
Adherence¶         x
Serious adverse events reporting**   x (immediate start after inclusion on day 0)
*Participants with concomitant deep vein thrombosis are excluded from further study participation (screening failures).
†At the baseline visit, participants are asked to fill in the PEmb- QoL questionnaire. For follow- up assessments, participants receive the PEmb- QoL 
including a prestamped envelope by mail and are asked to complete and return the questionnaire. If the follow- up interview is done in- person, the 
PEmb- QoL can be administered during the office visit.
‡ Functional status is assessed using the post- venous thromboembolism functional status scale.
§The first part of the patient diary consists of an information on the study outline, surveillance interviews, and symptoms and signs suggestive for 
recurrent venous thromboembolism and bleeding, the investigator’s contact information/emergency telephone number if these symptoms/signs 
occur, how to take the study medications, and instructions to return the drug bottles at the end of the study. The second part consists of a patient 
diary where patients are asked to record dates and type of outcomes and measures of health resource utilisation (eg, physician visits), and the time 
to symptom resolution and return to work/usual activities.
¶Adherence is assessed by counting the pill count of the returned medication bottles.
**A serious adverse event is defined as any untoward medical occurrence that results in in death, is life- threatening, requires inpatient hospitalisation 
or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. In addition, 
important medical events that may jeopardise the patient or may require an intervention to prevent one of these outcomes is also considered serious.
††Phone or in- person follow- up, depending on local practice.
‡‡See online supplemental file 2 for the case report form of the 10- day follow- up interview as an illustration of the content of the follow- up phone 
calls.
PEmb- QoL, Pulmonary Embolism Quality of Life.
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autopsy- confirmed PE in the absence of another more 
likely cause of death, (2) objectively confirmed PE within 
the last 48 hours before death in the absence of another 
more likely cause of death or (3) PE is not objectively 
confirmed, but is most likely the main cause of death.55 
Final classification of all medical outcomes is based on 
the full consensus of the committee.
Ancillary outcomes
Ancillary outcomes include health- related quality of 
life and functional status, both important patient- 
centred outcomes and medical resource utilisation, 
an economically relevant efficiency measure. Disease- 
specific, health- related quality of life at baseline, 30 
and 90 days after the index PE is assessed using the 
Pulmonary Embolism Quality of Life (PEmb- QoL) 
questionnaire.56 57 The PEmb- QoL is a validated, self- 
administered 40- item questionnaire to quantify quality 
of life in patients having experienced PE. Functional 
status is measured at 90 days after randomisation using 
the post- VTE functional status scale.58 59 This scale has 
been proposed to assess functional limitations after 
VTE, covering aspects of daily life (including limita-
tions in usual activity and changes in lifestyle) that are 
affected by the consequences of VTE and its complica-
tions. The assessment is done using a short, structured 
interview 90 days after randomisation.
The following measures of medical resource utilisa-
tion and productivity are assessed44 60: initial length of 
stay (LOS), subsequent overall hospitalisations as well as 
overall ED and physician outpatient visits within 90 days 
of randomisation, and time to return to work in workers 
or usual activities (eg, household) in non- workers. Infor-
mation on these outcomes are obtained from the partic-
ipant during the follow- up interviews, by interview of the 
patient’s primary care physician and by hospital chart 
review. Subsequent healthcare contacts are classified as 
potentially related to VTE if a patient had chest or leg 
symptoms or signs (dyspnoea, chest pain, pleural effusion 
or leg pain or swelling), or bleeding complications.
Withdrawals and loss to follow-up
Given the low treatment and follow- up burden and 
the short follow- up period of 90 days, we expect that 
completeness of follow- up data collection will be close to 
100% based on prior experience.44 A patient who with-
draws consent for follow- up at 10 or 30 days may still 
agree with passive follow- up (ie, that study personnel may 
collect follow- up information from medical records of 
the participant’s primary care physician) or to continue 
with the assessment at 90 days, if given the option. If 
study withdrawal occurs, data collected up to the time of 
withdrawal is used in a coded manner. If a participant is 
lost to follow- up, primary care physicians and surrogates 
are contacted, and the hospital records are consulted 
to obtain information about primary and secondary 
outcomes and survival status.
Post-hoc evaluation of radiological interobserver agreement
CTPA images undergo central review at the Bern Univer-
sity Hospital by a panel of two experienced thoracic radiol-
ogists blinded to the interpretation of the radiologist at 
the enrolling site. Based on the consensus of this panel, 
the initial CTPA readings are classified into three catego-
ries: (1) presence of isolated SSPE (true- positive isolated 
SSPE), (2) absence of any PE (false- positive isolated 
SSPE) and (3) presence of segmental, lobar or central PE 
(false- negative higher level PE). The panel also evaluates 
the technical quality of the CTPA examination (adequacy 
of opacification, breathing artefacts) and the number 
of filling defects (ie, single vs multiple isolated SSPE). 
Confirmation of the SSPE diagnosis prior to enrolling 
the patient is logistically not feasible due to the short 
timeline between diagnosis and enrolment, and it would 
not reflect real- world practice, thus limiting the external 
validity of our study results. Therefore, the central review 
of CTPA images is done post- hoc in 6- month batches.
Sample size calculation
Assumptions on VTE recurrence risk are based on 
data from 127 low- risk patients with isolated SSPE who 
received anticoagulants (warfarin or low- molecular- 
weight heparin), showing a VTE recurrence risk of 0.8% 
at 90 days after diagnosis.23 We chose an absolute non- 
inferiority margin of 3.5% on the basis of recruitment 
feasibility, clinical acceptability and previous studies. This 
corresponds to a difference which is considered accept-
able by most physicians and patients for the following 
reasons. First, our margin is within the range of the 
3- month VTE recurrence proportion (0.5%–5%) below 
which thrombosis specialists would not initiate antico-
agulation for PE.61 Second, the definition of a clinically 
acceptable non- inferiority margin for recurrent VTE 
must also take into account the potential benefits of with-
holding anticoagulation, that is, the substantially lower 
risk of clinically significant bleeding (<1% vs 7% within 
3 months for patients receiving anticoagulants).5 23 25 62 
Indeed, a patient group with PE who was involved in the 
trial planning process indicated that given the bleeding 
risk associated with anticoagulants, a VTE recurrence 
proportion of <5% seemed acceptable. Finally, similar 
non- inferiority margins (3%–5%) have been used in key 
studies comparing different drug treatment regimens 
and inpatient versus outpatient management for acute 
VTE.42 44 63–67
To determine the sample size, we used a Monte- Carlo 
simulation approach based on an Agresti- Caffo CI for 
risk difference.68 Assuming a baseline VTE recurrence 
proportion of 1.0% at 90 days in both treatment groups, 
an absolute margin of 3.5% defining non- inferiority for 
clinical surveillance and a sampling ratio of 1:1 allowing 
5% attrition (dropouts, including patients who died from 
non- VTE- related causes) in each group during 90 days, 
we estimated that 276 patients (138 per group) would 
result in at least 80% power to establish non- inferiority at 
an one- sided type I error of 5%.
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Planned statistical analyses
As recommended by the Consolidated Standards of 
Reporting Trials statement for non- inferiority trials,69 
we will perform both intention- to- treat (ITT) and per- 
protocol (PP) analyses. For the primary outcome, ITT and 
PP analyses should reach the same conclusion to consider 
results to be robust. For the remaining outcomes, the 
ITT analysis will be the primary analysis, the PP analysis a 
secondary analysis.
In the ITT analysis, all randomised patients will be 
analysed within the treatment group to which they were 
randomised. In the PP analysis, patients with protocol 
violations will be excluded (crossover to study treatment 
from other group; patients receiving a different type 
or dose of anticoagulation than requested by the study 
protocol; patients with missing primary outcome data; 
patients violating relevant eligibility criteria; patients 
stopping study treatment within 1 month after randomis-
ation, or patients in whom the diagnosis of isolated SSPE 
was refuted by the central CTPA review panel).
We will describe the prevalence of recurrent VTE, clini-
cally significant bleeding (including its individual compo-
nents, major and clinically relevant non- major bleeding), 
and all- cause mortality at 90 days after randomisation with 
95% Wilson CIs by treatment group. Non- inferiority of 
the primary outcome (VTE recurrence) among patients 
in the clinical surveillance versus the anticoagulation 
group will be assessed based on the Agresti- Caffo CI for 
risk difference.68 If the upper limit of the one- sided 95% 
Agresti- Caffo CI will be lower than the prespecified non- 
inferiority margin, clinical surveillance will be considered 
non- inferior to anticoagulation. For secondary outcomes, 
we will calculate the risk difference with a two- sided 95% 
Agresti- Caffo CI and compare groups using an exact bino-
mial test.68
PEmb- QoL dimension scores at 30 and 90 days as well 
as the change in scores from baseline will be presented 
by treatment group as means with 95% CIs. The change 
in dimension scores and the differences in the change 
between groups will be analysed using a repeated- 
measures, linear mixed- effects model adjusted for the 
respective baseline value. Functional status, which is 
measured on a scale from 0 (no functional limitations) 
to 5 (death) at 90 days, will be presented as median 
and IQR and compared between groups using the non- 
parametric Wilcoxon rank- sum test. Count data (subse-
quent hospitalisations, outpatient visits) will be presented 
by treatment group as rate with an exact 95% Poisson CI 
and compared using a rate ratio and exact p value. Time- 
to- event outcomes (initial LOS, time to return to work/
usual activities) will be presented as medians and IQRs. 
For LOS, we will compare groups using the Wilcoxon 
rank- sum test. For return to work, we will display Kaplan- 
Meier curves and compare groups by the log- rank test. 
An alpha level of <0.05 will define statistical significance.
In secondary analyses, we will calculate the cumulative 
incidence and the difference in cumulative incidence 
of VTE recurrence and clinically significant bleeding, 
correcting for withdrawals and losses to follow- up by 
censoring and for death unrelated to VTE recurrence 
or bleeding as a competing event. All- cause mortality 
will be assessed likewise, however, a competing event 
does not apply. In a further secondary analysis, we will 
use model- based approaches for all outcomes. For time- 
to- event outcomes (VTE recurrence, clinically significant 
bleeding, LOS, return to work/usual activity), we will use 
competing risk regression according to Fine and Gray,70 
accounting for non- VTE/non- bleeding- related death or 
all- cause death as a competing event. For mortality, we 
will use Cox regression. For count data, we will use a nega-
tive binomial model, and also consider zero- inflation. In 
case of heterogeneity across sites, we will adjust models 
for site using random- effects models.
Data monitoring and interim safety analysis
An independent Data and Safety Monitoring Board 
(DSMB) consisting of three members unaffiliated with any 
of the participating institutions will evaluate unblinded 
interim safety results after 100 and 190 randomised 
patients have completed the 90- day follow- up. To monitor 
recurrent VTE in the intervention group, formal interim 
analyses will be performed using a Bayesian approach. 
Based on literature,23 we expect a frequency of VTE recur-
rence of 1.0% (0%–4.5%). We regard a frequency of >5% 
in the surveillance group as clinically unacceptable. We 
will calculate the prior probability distribution of events 
based on the expected frequency as well as the posterior 
probability distribution using actually observed data at 
each interim analysis. Based on the posterior distribution, 
we will calculate the probability that the true proportion 
of VTE recurrence in the surveillance group exceeds 
the threshold of unacceptable frequency. If the prob-
ability of exceedance is >70%, the surveillance arm will 
be considered inferior and the DSMB will recommend to 
stop the trial. The final decision will lie with the Steering 
Committee. This procedure is conservative regarding the 
type I error rate; therefore, we will not adjust the signifi-
cance level in the final analysis.
Patient and public involvement
We have partnered with a group of patients who had 
recently experienced PE in the planning process of this 
trial, including the selection of patient- centred outcomes, 
the establishment of a safe surveillance schedule and the 
determination of a clinically acceptable non- inferiority 
margin. Patients are not involved in the recruitment and 
conduct of the study or the dissemination of study results.
Data sharing
After publication of the study results, a de- identified 
patient- level data set relating to the primary publication 
along with the latest version of the study protocol, the 
informed consent form, the statistical analysis plan, the 
analysis code and the data management plan of the study 
will be made publicly available in the Bern Open Repository 
and Information System (BORIS) Research Data.
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ETHICS AND DISSEMINATION
This trial is conducted in accordance with the Declaration 
of Helsinki, the International Council on Harmoniza-
tion Good Clinical Practice guidelines, and all applicable 
national legal and regulatory requirements. Authorisation 
by the local Ethics Committees and Swissmedic has been 
obtained in Switzerland, and the submission process to 
the relevant Dutch and Canadian Ethics Committees and 
regulatory authorities is ongoing. All changes in research 
activity or unanticipated problems involving risks to human 
subjects will be reported promptly to the ethics commit-
tees. All participating investigators/institutions will permit 
study- related monitoring, audits, ethics committee reviews 
and regulatory inspections, and will provide direct access 
to source documents and data. Protection of confidenti-
ality is ensured according to regulatory requirements.
Study personnel informs eligible patients with a diag-
nosis of isolated SSPE about all aspects of the study partic-
ipation, including the goals, procedures and potential 
risks/benefits associated with the study. Potential partic-
ipants are informed that the decision to participate in 
the study is entirely voluntary and that they may with-
draw from the study at any time, with no effect on their 
current or future treatment. Written informed consent 
is obtained from all eligible patients prior to any study- 
related procedure, including bilateral whole- leg CUS. 
The primary study results will be presented at scientific 
conferences and published in a peer- reviewed medical 
journal. We also plan local presentations for physicians 
at the participating sites. Participants will receive a letter 
with the study results explained in lay language. Further 
public dissemination of the results is planned through 
publications in the lay press and via social media.
CONCLUSION
The SAFE- SSPE trial addresses an important gap of knowl-
edge, the optimal management of SSPE, and represents 
the first randomised, direct comparison of clinical surveil-
lance alone versus anticoagulant treatment for low- risk 
patients with isolated SSPE. As the number of SSPE 
patients who may eventually receive anticoagulant treat-
ment is likely to rise in the future with the further dissem-
ination and advancement of CTPA technology, a strong 
scientific basis for withholding anticoagulation in low risk 
patients with SSPE is urgently needed. The results of this 
trial have the potential to improve quality and efficiency 
of care by reducing bleeding episodes and resource utili-
sation and increasing health- related quality of life.
Current status of the SAFE-SSPE trial
Patient recruitment has started in May 2020; by July 2020, 
six patients have been enrolled in the trial. Follow- up 
of the last participant is expected to be completed in 
February 2024.
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